Opinion

Video

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Author(s):

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

Video content above is prompted by the following questions:

  1. Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
    1. What was the objective of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=155
      2. Median follow-up: 21.78 months
      3. PFS
      4. ORR
      5. Median duration of response
      6. OS
      7. Safety
  2. Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
  3. Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?
Related Videos
Surbhi Sidana, MD, MBBS
IMS Recap
Rahul Banerjee, MD, FACP
Anant Madabhushi, PhD.
Rahul Banerjee, MD, FACP.
Leland Metheny, MD, University Hospitals Seidman Cancer Center
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Don M. Benson, MD, PhD, James Cancer Hospital
November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

Maggie L. Shaw
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Neon CAR T graphic | Image Credit: © kalpis-stock.adobe.com
November 7th 2024

Eque-Cel CAR T Shows Strong Results for Multiple Myeloma

Maggie L. Shaw
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.
Screenshot of an interview with Courtney VanHouzen, PharmD
October 15th 2024

Making Cancer Care Easier With Community Bispecific Antibody Programs

Alexandra Gerlach Laura Joszt, MA
Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.
Thomas Jefferson | Image: Thomas Jefferson University
October 13th 2024

Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

Ryan Flinn
Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com
October 11th 2024

Delays in Myeloma Oral Therapy Linked to Race, Age

Maggie L. Shaw
Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo